Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Accenture Backs Earli's Innovative Cancer Detection Tech, Boosting Global Health Collaborations

Author: Benzinga Newsdesk | August 19, 2024 08:00am

Accenture (NYSE:ACN) has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company that developed a novel approach to early cancer detection with a synthetic targeting platform that selectively reprograms cancer cells to reveal and destroy themselves. This investment from Accenture Ventures will support expanding collaborations with global health and pharma companies that can use Earli's technology to more rapidly and accurately detect and treat cancer.

Posted In: ACN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist